BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26362408)

  • 1. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
    Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
    Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
    De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
    Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
    Chen YX; Li Y; Zhang LY; Liu X; Shan NN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM.
    Wautier MP; El Nemer W; Gane P; Rain JD; Cartron JP; Colin Y; Le Van Kim C; Wautier JL
    Blood; 2007 Aug; 110(3):894-901. PubMed ID: 17412890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
    Tefferi A
    Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.
    De Grandis M; Cassinat B; Kiladjian JJ; Chomienne C; El Nemer W
    Am J Hematol; 2015 Jul; 90(7):E137-8. PubMed ID: 25809027
    [No Abstract]   [Full Text] [Related]  

  • 15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 19. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.
    Brusson M; De Grandis M; Cochet S; Bigot S; Marin M; Leduc M; Guillonneau F; Mayeux P; Peyrard T; Chomienne C; Le Van Kim C; Cassinat B; Kiladjian JJ; El Nemer W
    Haematologica; 2018 Jun; 103(6):972-981. PubMed ID: 29599206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.